The proteasome inhibitor, bortezomib, has been demonstrated to sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis. Natural killer (NK) cells represent potent antitumor effector cells. They also express TRAIL. Therefore, we investigated whether bortezomib could sensitize tumor cells to NK cell-mediated killing, and have the same effect in human prostate cancer cell lines (LNCaP and DU145). We found that bortezomib strongly inhibits proliferation in both cell lines. Furthermore, compared with LNCaP cells, DU145 cells are more sensitive to bortezomib-induced apoptosis. However, bortezomib is unable to sensitize these two cell lines to NK cell-mediated killing in short-term assays. In long-term assays, we found that killing mediated by activated NK cells following bortezomib treatment leads to greater antitumor effects than either treatment alone. In addition, treatment with bortezomib causes these cells to upregulate apoptosis-related mRNA as well as death receptors and downregulate the major histocompatibility class (MHC)-I molecule on the cell surface of DU145 cells. In contrast, LNCaP cells are not sensitized by this treatment. Death receptors and the MHC-I molecule did not change in this cell line. These data suggest that bortezomib can be used to sensitize prostate cancer cells to NK cell-mediated killing and improve current cancer therapies. This therapeutic strategy may be more effective in patients with androgen-insensitive prostate cancer.
INTRODUCTION
Prostate cancer is the most common malignant tumor in men and the second leading cause of cancer death in the United States and Europe. In recent years, following the progress of diagnostic techniques, the incidence has increased in Asia. 1 Most prostate cancer patients encounter tumor recurrence within 1-3 years after treatment. At this stage, prostate cancer loses androgen-dependency and becomes androgen-or hormone-insensitive or refractory and the prognosis is very poor. 2 Therefore, new treatment modalities are required.
Immunotherapy is a promising treatment modality for malignant tumors. Natural killer (NK) cells are a subset of lymphocytes capable of mediating cytotoxicity against tumor cells and virally infected cells, and thus constitute a key component of the innate immune system. 3 NK cells lyse tumor targets directly via the perforin/granzyme pathway. They also express Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which directly triggers death receptor pathways inducing tumor apoptosis. 4 Death receptors including Fas, TNFR1, TRAIL-R1/DR4, TRAIL-R2/DR5, DR3 and DR6 share a conserved death domain that is triggered by adaptor molecules which activate executioner caspases and initiate apoptosis. 5 Recognition of targets by NK cells is regulated through a balance of activated and inhibitory signals. Even in the presence of an activated ligand, inhibitory ligands can initiate overriding signals that culminate in a net suppression of NK-cell function. NK cells recognize major histocompatibility class (MHC) I and class I-like molecules through surface expression of killer immunoglobulin-like receptors (KIRs). MHC I molecules on tumor cells ligate NK cell-inhibitory KIR, and suppress NK-cell function. The inactivation of NK cells by self-human leukocyte antigen (HLA) molecules is a potential mechanism by which malignant cells evade host NK cell-mediated immunity. 6 Bortezomib, a proteasome inhibitor, has been approved for the treatment of multiple myeloma, and is currently being investigated in other cancers as a single agent or in combination with chemotherapeutic regimens. 7 It selectively binds to and inhibits the chymotrypticlike activity of the proteasome at nanomolar concentrations. Proteasome inhibition is associated with decreased tumor proliferation and increased apoptosis. 8 Sayers et al. 9 previously showed that bortezomib could sensitize tumor cells to TRAIL-mediated lysis, in part due to a reduction in the anti-apoptotic protein cellular FLICE inhibitory protein. TRAIL represents one cytotoxic pathway used by immune effector cells such as T and NK cells to lyse target cells. These immune effector cells have been shown to mediate potent antitumor effects both in vitro and in vivo. 10 Here, we examine two well-known human prostate cancer cell lines (LNCaP and DU145). LNCaP retains many features of earlystage disease (androgen-sensitive and non-metastatic). In contrast, DU145 is not only locally aggressive but also highly metastatic, and it has a low expression of androgen receptor protein and nonresponsiveness of androgen receptor to androgens in vitro and in
vivo.
11 In our present study, we want to study whether bortezomib could sensitize prostate cancer cells to NK cell-mediated killing and its mechanism. This study may supply a more effective therapeutic strategy for androgen-insensitive prostate cancer.
MATERIALS AND METHODS

Preparation of NK cells
Human NK cells were isolated by negative depletion of peripheral blood mononuclear cells obtained from healthy volunteers using the NK cell isolation kit (R&D, Minneapolis, MN, USA) according to the manufacturer's protocol. Briefly, the Percoll discontinuous density gradient centrifugation method was used to isolate peripheral blood mononuclear cells. Cells at a density of 1310 8 cells ml 21 were suspended in cold reaction buffer prior to the procedure. Cells (1310 8 cells, 0.5-1.0 ml volume) were transferred into a 5-ml tube. A 25-ml volume of biotinylated antibody was added. The cell-antibody suspension was gently mixed, avoiding bubble formation, and incubated at 4uC in a refrigerator for 15 min. Fifty microliters of MagCellect beads were added to the cell suspension, mixed gently and incubated at 4uC in a refrigerator for 15 min. At the end of the incubation period, the cell suspension was transferred to a 50-ml conical centrifuge tube, and the cells were washed with 15 volumes of reaction buffer and centrifuged at 300 g for 8 min. The supernatant was completely pipetted out, and the cell pellet was resuspended in 2 ml of reaction buffer and transferred to a new 5-ml tube. The tube was placed in a MagCellect Magnet that had been positioned horizontally to accommodate 5-ml tubes and incubated for 6 min at room temperature. Magnetically tagged cells will migrate toward the magnet, leaving the unwanted cells in suspension. While the tube was in the magnet, the reaction supernatant was carefully aspirated using a pipette and discarded. The tube containing the desired magnetically trapped cells was removed from the magnet and the cells were resuspended in 2 ml of reaction buffer by gently pipetting up and down. This step was repeated. The resultant cell fraction contained the NK cells. The NK cells were cultured in RPMI 1640 medium (GIBCO BRL, Gaithersburg, MD, USA) supplemented with 10% fetal calf serum (FCS; HyClone, Logan, UT, USA), and 500 U ml 21 recombinant human IL-2 (Roche, Nutley, NJ, USA) for 24 h to activate the NK cells. The purity of human NK cells was typically greater than 85% as determined by staining for CD3, CD16 and CD56 (Biolegend, San Diego, CA, USA), respectively ( Figure 1 ). Written informed consent was obtained from each healthy volunteer in accordance with the Declaration of Helsinki for the use of cells from leukapheresis products for research, according to the requirements of the Institutional Review Board of the National Heart, Lung, and Blood Institute (Bethesda, MD, USA).
Cell culture
The LNCaP and DU145 prostate cancer cell lines were obtained from American Type Culture Collection (Rockville, MD, USA). The LNCaP cells were maintained in F12 medium (GIBCO BRL), and the DU145 cells were cultured in RPMI 1640 medium (GIBCO BRL). All cell lines were supplemented with 10% (v/v) FCS (HyClone) and incubated at 37 uC with 5% CO 2 .
Reagents Bortezomib (PS-341; Velcade) was provided by Millennium Pharmaceuticals (Cambridge, MA, USA). Stock solutions of bortezomib were made at 1 mg ml 21 in phosphate-buffered saline and frozen at 280 uC. The stock solutions were thawed and diluted to 1 mg ml 21 with RF-10 complete medium and used within 2 weeks of dilution. Bortezomib solutions were protected from light at all times.
Flow cytometry
The LNCaP and DU145 cells were seeded onto six-well plates at a density of 2.0310 5 cells per 2 ml complete medium and allowed to attach for 24 h. Following this incubation, the cells were washed once with serum-free F12 or RPMI 1640 and replaced with a medium containing 10% FCS and 0 nmol l 21 or 20 nmol l 21 bortezomib and incubated for 24 h. Cells were then digested using trypsogen. Approximately 2310 5 LNCaP and DU145 cells per sample were brought to a single-cell suspension and washed with blocking buffer (1% fetal bovine serum and 1% human antibody serum in phosphatebuffered saline). Cells were labeled with phycoerythrin (PE)-anti-DR5 (DJR2-4), PE-anti-Fas (DX2) and PE-anti-HLA-A, B, C (W6/ 32) (Biolegend, San Diego, CA, USA). Cellular labeling was performed 
Proliferation and killing assay
The LNCaP and DU145 cells were suspended in F12 or RPMI 1640 medium with 10% FCS at a concentration of 1310 4 cells ml 21 . The cell suspension in 100 ml was added to 96-well flat-bottomed culture plates and incubated at 37 uC, in 5% CO 2 for 24 h. After the cells adhered, bortezomib was added to the wells at the following concentrations: 0, 5, 10, 15, 20 and 25 nmol l 21 . F12 or RPMI 1640 medium with 10% FCS was used as a negative control and incubated at 37 uC, in 5% CO 2 for 24, 48 or 72 h. For the killing assay, 10 or 20 nmol l 21 bortezomib was incubated for 24 h. After incubation, 10 ml CCK-8 kit (Dodindo Laboratories, Kumamoto, Japan) was added to each well, oscillated for 1 min on an oscillator and incubated at 37 uC and in 5% CO 2 for 1.5 h continuously. After incubation, absorbances were read on a Dynatech MR 5000 plate reader at 490 nm. This experiment was repeated five times.
Apoptosis detection kit (annexin-V binding)
This assay was performed according to the manufacturer's instructions. LNCaP and DU145 cells were seeded onto six-well plates and incubated for 24 h, and then treated with 0, 5, 10, 15, 20 and 25 nmol l 21 bortezomib. After 24 h, the cells were trypsinized, counted and sedimented, then washed with cold phosphate-buffered saline and resuspended in 500 ml binding buffer. FITC-conjugated annexin-V (10 ml) and propidium iodide (10 ml) (Keygen, Nanjing, China) were added to each sample, and the mixture was incubated at 4 uC in the dark for 5 min. The cells were then immediately subjected to FACS analysis (BD FAC-S Calibur, San Jose, CA, USA).
Quantitative real-time PCR Total RNA was isolated from cells using Trizol reagent (Invitrogen, Carlsbad, CA, USA). RNA (500 ng) was then reverse transcribed into complementary DNA using oligo(dT) primers and AMV Reverse Transcriptase (Takara, Shiga, Japan). Complementary DNA was synthesized by incubating the reaction mix at 25 uC for 5 min, 42 uC for 30 min and 85 uC for 5 min. cDNA samples were stored at 220 uC until use.
Quantitative real-time PCR was performed using the MyiQ realtime PCR detection system (Bio-Rad, Irvine, CA, USA). PCR was carried out in a 50-ml reaction volume: 25 ml of iQ SYBR Green Supermix, 0.5 ml each of specific primer mix (100 nmol l 21 as the final concentration of each primer), 2 ml of complementary DNA and 19 ml of nuclease-free water. Samples were run in duplicate in 96-well plates (Bio-Rad). The primers used for quantitative real-time PCR were as follows: DR5: forward 59-AGCTAAGTCCCTGCACCACGA 39, reverse 59-TGTACAATCACCGACCTTGACCA-39;
Fas: forward 59-CAACAACCATGCTGGGCATC-39, reverse 59 TGATGTCAGTCACTTGGGCATTAAC 39; HLA-C: forward 59-TCCTGGTTGTCCTAGCTGTC-39, reverse 59-CAGGCTTTACAAGTGATGAG-39; GAPDH: forward 59-GAAGGTGAAGGTCGGAGTC-39, reverse 59-GAAGATGGTGATGGGATTTC-39.
The PCR cycles consisted of denaturation at 95 uC for 15 s, and annealing as well as extension at 60 uC for 1 min for 40-60 cycles. Each sample was analyzed twice. The threshold cycle (Ct) was defined as the fractional cycle number at which the fluorescence exceeds the given threshold. The obtained data were translated into the log2 scale. The 2
2DDCt method was used to analyze the relative expression of the target gene.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 4 software (GraphPad, San Diego, CA, USA). One-way and two-way analysis of variance were used where appropriate.
RESULTS
Bortezomib inhibits viability and proliferation on both DU145 and LNCaP cells
We sought to determine if the DU145 and LNCaP cell lines would display sensitization to bortezomib in terms of viability and proliferation. The effects of bortezomib on DU145 and LNCaP cells are shown in Figure 2 . The proliferation of tumor cells was determined by CCK-8 after DU145 and LNCaP cells had been exposed to varying concentrations of bortezomib for 24, 48 or 72 h. Cells incubated with 15, 20 or 25 nmol l 21 bortezomib displayed a significant decrease (P,0.01) in proliferation after 48 h (Figure 2 ).
Bortezomib induces apoptosis in both DU145 and LNCaP cells DU145 and LNCaP cells were exposed to varying concentrations of bortezomib for 24 h, and then apoptosis was analyzed using annexin-V and propidium iodide. DU145 cells displayed a slight, but significant (P,0.01) increase in apoptosis at or above 15 nmol l 21 of bortezomib, Human prostate cancer cells sensitization to NK cell killing by bortezomib W Hu et al 697 whereas higher concentrations were required to stimulate significant apoptosis in LNCaP cells (Figure 3 ). (Figures 2 and 3) . The treated DU145 and LNCaP cells were cocultured with 1 : 1, 4 : 1, 16 : 1 and 32 : 1 effector-to-target (E : T) ratios for 24 h, and then washed and assayed using CCK-8. Only a slight increase in NK-mediated lysis was observed in these short-term assays (Figure 4) . We hypothesized that in order to see the effects of other modes of NK cell cytotoxicity, a long-term assay would be needed.
Bortezomib increases mRNA levels of DR5 and Fas and decreases the expression of HLA-C in DU145 cells, but not in LNCaP cells Previous studies have demonstrated that bortezomib increases the surface expression of death receptors on mouse leukemia cells. 12 We sought to determine if bortezomib treatment would increase the amount of DR5 and Fas genes in the human prostate cancer line. DU145 and LNCaP cells were exposed to varying amounts of bortezomib for 24 h and then mRNA levels were determined by real-time PCR analysis. With incremental bortezomib concentrations, DU145 cells displayed an insignificant but marked increase in the levels of DR5 and Fas (P,0.01). However, these genes showed very small changes in LNCaP cells. The inactivation of NK cells by self-HLA molecules is a potential mechanism by which malignant cells evade host NK cellmediated immunity, particularly HLA-C and Bw4 molecules. 13 We detected the expression of HLA-C in these two cell lines. We found that, the expression of HLA-C was decreased after treatment with bortezomib in DU145 cells (P,0.01), but not in LNCaP cells ( Figure 5 ).
Bortezomib treatment increases the surface expression of DR5 and Fas and decreases the expression of HLA-A, B, C in DU145 cells, but not in LNCaP cells
To determine if the increase in death receptor mRNA correlated with an increase in cell surface expression, we used flow cytometry to determine the surface levels of DR5, Fas and HLA-A, B, C with or without bortezomib treatment. DU145 and LNCaP cells were maintained in normal culture conditions or treated with 20 nmol l 21 bortezomib for 24 h before labeling with PE-conjugated anti-DR5, antiFas and anti-HLA-A, B, C. In DU145 cells, the surface expression of both DR5 and Fas was upregulated in cells which received bortezomib treatment, and the expression of HLA-A, B, C was decreased (P,0.01). In contrast, all three proteins in LNCaP cells were not expressed ( Figure 6 ). These data correspond with the death receptor mRNA expression displayed in Figure 5 . 
Human prostate cancer cells sensitization to NK cell killing by bortezomib W Hu et al 698
Bortezomib-treated prostate cancer cells are sensitized to NK killing in the long-term assays Only a slight increase in NK cell killing of prostate cancer cells after bortezomib sensitization was observed in the short-term cytotoxicity assays ( Figure 4) . Therefore, we hypothesized that bortezomib sensitization would increase markedly if we used a longer-term assay. To address this, we treated DU145 and LNCaP cells with or without 20 nmol l 21 bortezomib for 48 h. The cells were then counted, equal numbers were plated and the cells were allowed to adhere to plates for 24 h. NK cells were activated by adding 500 U ml 21 recombinant human IL-2 for 24 h. Tumor cells were washed and incubated with activated NK cells at an E : T ratio of 1 : 1 for 6 days. All cells were then removed from the plates and apoptosis was analyzed using annexin-V and propidium iodide. The 6-day period in which the tumor cells were exposed to NK cells allowed killing through multiple mechanisms to occur, including the ligation of death receptors. 12 Bortezomib pretreatment resulted in a decreased number of live tumor cells and increased apoptosis after the 6-day period in both DU145 and LNCaP cells (P,0.01). The effects of this treatment were more pronounced in DU145 cells compared with LNCaP cells (P,0.001). NK cells effectively increased the rate of apoptosis in cells in all groups. However, the combination of NK cells and bortezomib pre-treatment resulted in a decrease in proliferation that was lower than each treatment alone (Figure 7) . DISCUSSION Molecular targeting in cancer treatment offers great promise in the selective attack of tumor cells. In particular, the augmentation of immune attack will be an effective therapy which could selectively kill rebirth tumor cells in the future.
14 Transient proteasome inhibition may provide a manageable therapeutic 'window' for the use of proteasome inhibitors in cancer therapy. Other investigators have demonstrated that bortezomib can augment NK cell-mediated killing of mouse leukemia cells. 12 In this report, we demonstrate that bortezomib 15, 16 We also found that bortezomib was unable to efficiently sensitize these two cell lines to NK cell-mediated killing in short-term assays. In long-term assays, we found that killing by activated NK cells following bortezomib treatment led to greater antitumor effects than either treatment alone. In addition, treatment of DU145 cells with bortezomib led to a dose-dependent increase in the transcription of apoptosis-related genes and a decrease in MHC-I molecule genes. These data also correlated with an increase in the surface expression of death ligand receptors DR5 and Fas and downregulation of the MHC-I molecule. In contrast, LNCaP cells were not sensitized by this treatment. The death receptors or MHC-I molecule did not change in this cell line.
Killing via cytotoxic granules has been shown to be the primary mechanism by which NK cells kill in short-term in vitro assays, 17 although these short-term assays do not reflect the engagement of death ligands on tumor targets. Therefore, it may be more informative to use longer-term assays in which NK cells can use their full complement of killing pathways; these conditions may be a better predictor of how effective the NK cells function. We demonstrate that bortezomib sensitized DU145 and LNCaP cells to killing by activated NK cells. The killing of bortezomib-treated targets in short-term killing assays was not augmented, and enhancement was only observed in long-term tumor outgrowth studies. Furthermore, sensitization was more obvious in DU145 cells.
The precise molecular mechanism by which proteasome inhibition acts to elicit its anticancer apoptotic activity has been difficult to resolve and is likely to be multifactorial. This is largely due to the vast number of cellular pathways regulated by the 26S proteasome. We found that bortezomib-pre-treated DU145 and LNCaP cells showed increased surface expression of death receptors DR5 and Fas which correlated with an increase in the transcription apoptotic genes, whereas in LNCaP cells, we did not observe these changes. NK cells possess TRAIL and Fas ligand (FasL), both of which can trigger apoptosis in target cells. These combined effects may present a mechanism by which bortezomib increases the susceptibility of tumor cells to NK cell-mediated killing. This, in part, may explain why bortezomib induced a higher level of apoptosis in DU145 cells. We also observed that activated NK cells slightly increased the percentage of apoptosis in LNCaP cells pre-treated with/without bortezomib after 6 days of coculturing. It is possible that bortezomib can also augment the cytokines produced by NK cells, notably interferon-c and tumor necrosis factor, which may be capable of engaging other death pathways, especially at lower E : T ratios. 4 However, the increase in death receptors and other components of extrinsic apoptosis does not explain the apparent increase in intrinsic apoptosis. Changes in intrinsic proapoptotic proteins (PUMA, Bax, and so on) or anti-apoptotic proteins (Bcl-2, Bcl-xL, and so on) are probably responsible.
Haplo-identical donor NK cells have been transfused in combination with an autograft in patients with multiple myeloma or after immunosuppression for acute leukemia or renal cell carcinoma. 18 These studies have demonstrated the activity of haplo-identical KIR-L-mismatched NK cells; however, therapeutic efficacy has been hampered as only a sub-population of the transferred NK cells was found to be allo-reactive. The bortezomib-induced downregulation of HLA class I and enhanced NK cell-mediated killing indicate that bortezomib can recruit nonalloreactive NK-cell populations. These effects suggest that bortezomib may play an important role in potentiating the antitumor activity of allogeneic KIR-L-mismatched NK cells.
Under normal circumstances, prostate cancer cells display self-HLA molecules, which inactivate autologous NK cells. This also helps to explain the relative lack of activity of adoptively transfused autologous NK cells in the solid tumor setting. In our study, we observed that treatment of DU145 cells with bortezomib led to a decrease in the surface expression of the HLA-ABC protein and HLA-C gene. Owing to cancer cells showing less MHC-I than normal cells, in long-term tumor outgrowth studies, we should see more apoptotic cells die in target coculture with NK cells compared with target cells alone. This demonstrated that bortezomib can overcome KIR-L inhibition of NK cells by prostate cancer cells and make adoptive NK-cell therapy more effective and widen its application. These changes were not observed in LNCaP cells. It is possible that bortezomib kills LNCaP cells in some other way. However, some investigators have observed that human NK cells were highly sensitive to bortezomib in vitro. 12 The half-life of bortezomib is short, and serum levels present 48 h after a dose of bortezomib did not adversely affect NK-cell function. However, its function in vivo remains unclear. More studies to identify whether bortezomib could sensitize prostate cancer to NK cellmediated killing in vivo, and tests to ascertain its safety, feasibility and efficacy could be future directions.
Recent progress defines molecular alterations and the contributions to prostate cancer progression and metastasis; however, there is a general consensus that current therapeutic strategies are relatively inactive in patients with androgen-insensitive cancer. The results of this study and others demonstrate that bortezomib can enhance the antitumor ability of NK cells. This effect can be utilized to sensitize solid tumors to NK cell-mediated killing and improve current cancer therapies. This therapeutic strategy may be more efficient in patients with androgen-insensitive prostate cancer.
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